Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant temozolomide vs temozolomide + bevacizumab in unresectable glioblastoma
2009-010337-45Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Grupo Español de Investigación en Neurooncología. Primary endpoint: Objective response after neoadjuvant treatment. Started Feb 2009; status: completed.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-010337-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010337-45.